Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3
European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2018.08.011
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
Elsevier BV